Published in Clin Exp Nephrol on October 20, 2011
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol (2001) 4.36
Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J (1973) 4.13
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant (2007) 2.68
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int (2005) 1.96
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest (1993) 1.85
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int (2003) 1.82
Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int (1997) 1.71
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int (2005) 1.64
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol (2003) 1.35
Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial (2008) 1.31
Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol (1997) 1.19
Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial (2008) 1.06
Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron (1994) 1.05
Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab (2009) 1.04
Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int (2000) 0.95
Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial (2006) 0.94
Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens (1997) 0.91
Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2003) 0.90
Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol (2004) 0.89
Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume. Kidney Int Suppl (2003) 0.86
Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis (2000) 0.84
Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol (2005) 0.83
Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial (2008) 0.82
Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. Clin Nephrol (2007) 0.81
Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial (2008) 0.81
CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol (2007) 0.80
Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol (2006) 0.76
Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result. Ther Apher Dial (2007) 0.75
Management of secondary hyperparathyroidism of dialysis patients. Nephrology (Carlton) (2003) 0.75
A strict low protein diet during the predialysis period suppresses peritoneal permeability at induction of peritoneal dialysis. Perit Dial Int (2009) 2.58
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial (2013) 2.07
Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol (2012) 1.94
Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant (2012) 1.52
Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant (2003) 1.29
Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis (2011) 1.05
Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol (2008) 1.00
Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant (2005) 0.99
Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun (2007) 0.95
Reversible posterior leukoencephalopathy syndrome after blood transfusion in a patient with end-stage renal disease. Clin Exp Nephrol (2011) 0.93
Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int (2003) 0.92
Cerebral microhemorrhage in Marchiafava-Bignami disease detected by susceptibility-weighted imaging. Neurol Sci (2012) 0.92
Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int (2009) 0.91
Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol (2010) 0.90
Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial (2010) 0.90
Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol (2004) 0.89
Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med (2010) 0.88
Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol (2004) 0.86
Clinical Expectation of Online Hemodiafiltration: A Japanese Perspective. Blood Purif (2015) 0.86
Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta (2006) 0.86
Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial (2011) 0.85
Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol (2009) 0.84
Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol (2009) 0.84
Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial (2005) 0.84
Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta (2007) 0.84
Vitamin D and vascular calcification in chronic kidney disease. Bone (2009) 0.83
Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant (2003) 0.82
Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int (2002) 0.81
Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2010) 0.81
Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond) (2012) 0.81
Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. Nephrol Dial Transplant (2003) 0.80
Novel markers of left ventricular hypertrophy in uremia. Am J Nephrol (2010) 0.80
CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol (2007) 0.80
Cystic beta2-microglobulin amyloidoma in a patient on long-term hemodialysis. Clin Exp Nephrol (2006) 0.79
Biocompatible characteristics of high-performance membranes. Contrib Nephrol (2011) 0.79
Involvement of matrix metalloproteinase-2 in the development of medial layer vascular calcification in uremic rats. Ther Apher Dial (2011) 0.79
Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial (2014) 0.79
Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients. Clin J Am Soc Nephrol (2010) 0.78
Nephrologist care for 12 months or more increases hemodialysis initiation with permanent vascular access. Clin Exp Nephrol (2011) 0.78
Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: the first multi-institutional joint study in Japan. Haematologia (Budap) (2002) 0.78
Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther Apher Dial (2006) 0.77
Assessment of inflow of endotoxin and its fragments in patients on maintenance hemodialysis. Blood Purif (2011) 0.77
Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response. Clin J Am Soc Nephrol (2013) 0.77
A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate. Intern Med (2012) 0.77
False-positive Results Obtained for Immunoglobulin M Antibody Tests of Cerebrospinal Fluid for Herpes Simplex Virus in a Patient with Varicella Zoster Virus Encephalitis. Intern Med (2015) 0.77
Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients. J Clin Endocrinol Metab (2014) 0.77
Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease? Expert Opin Investig Drugs (2014) 0.76
Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progression. Am J Nephrol (2011) 0.76
[Pathogenesis of secondary hyperparathyroidism and renal bone disease]. Clin Calcium (2004) 0.76
High free serum acrolein levels in bacterial infection and other disease states associated with oxidative stress: a potential biomarker? Clin Chem Lab Med (2007) 0.76
Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats. Physiol Rep (2013) 0.76
Clinical uses of 22-oxacalcitriol. Curr Vasc Pharmacol (2014) 0.75
New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients. NDT Plus (2008) 0.75
Clinical significance of parathyroid intervention on CKD-MBD management. NDT Plus (2008) 0.75
Cerebellar symptoms in a case of acute limbic encephalitis associated with autoantibodies to glutamate receptors δ2 and ɛ2. Clin Neurol Neurosurg (2012) 0.75
The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta (2008) 0.75
Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial (2007) 0.75
Clinical Effectiveness of Intermittent Infusion Hemodiafiltration Using Backfiltration of Ultrapure Dialysis Fluid Compared with Predilution On-Line Hemodiafiltration. Contrib Nephrol (2016) 0.75
[Calcium sensing receptor (CaR) agonist]. Nihon Naika Gakkai Zasshi (2005) 0.75